Teva Pharmaceuticals
TEVA
456 hedge funds and large institutions have $3.8B invested in Teva Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 140 increasing their positions, 131 reducing their positions, and 28 closing their positions.
82% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 28
21% more call options, than puts
Call options by funds: $362M | Put options by funds: $300M
4% more funds holding
Funds holding: 438 → 456 (+18)
7% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 131
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
1.09% less ownership
Funds ownership: 46.66% → 45.57% (-1.1%)
21% less capital invested
Capital invested by funds: $4.83B → $3.8B (-$1.03B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$67.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$47.3M |
| 3 |
GAM
Goldentree Asset Management
New York
|
+$33.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$18.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$340M |
| 2 |
D.E. Shaw & Co
New York
|
-$20.2M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$18.4M |
| 4 |
State Street
Boston,
Massachusetts
|
-$15.2M |
| 5 |
Millennium Management
New York
|
-$11.7M |
TEVA Hedge Fund Activity: Q2 2022 in Review
456 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2022, worth a combined $3.8B — down 21% from $4.83B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new TEVA positions and 28 closed out — a net gain of 23 holders — while 140 added to existing stakes and 131 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $67.8M. The largest seller was Capital Research Global Investors, cutting an estimated $340M.
- 456 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2022, up from 438 in Q1 2022.
- Funds reported $3.8B of Teva Pharmaceuticals stock for Q2 2022, down 21% quarter-over-quarter.
- 51 funds opened new Teva Pharmaceuticals positions in Q2 2022 and 28 closed out, a net change of +23 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2022 was Citadel Advisors, an estimated $67.8M added.
- The largest Teva Pharmaceuticals seller in Q2 2022 was Capital Research Global Investors, an estimated $340M sold.
Based on aggregated 13F filings for Q2 2022.